Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 ...
An outdoor sign outside Cinderella Plastic Surgery Hospital, Seoul, reads, “Do you want to be Cinderella?” (Morgan Norris) I ...
Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease, affecting up to one in three people in the general population, with an ...
Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...
The subcutaneous formulation of toripalimab demonstrated noninferior pharmacokinetics compared to the intravenous version in ...
New Vision Med Spa has opened in downtown Columbia. It offers microneedling, IV hydration, skincare, help with diabetes and ...
Bertolotti’s syndrome is a rare and often misdiagnosed condition among individuals experiencing pain in their lower back or spine. In 2023,, III, MD, authored a paper, published in World Neurosurgery, ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback